MX2015017123A - Compuestos de platino a base de lipido y nanoparticulas. - Google Patents

Compuestos de platino a base de lipido y nanoparticulas.

Info

Publication number
MX2015017123A
MX2015017123A MX2015017123A MX2015017123A MX2015017123A MX 2015017123 A MX2015017123 A MX 2015017123A MX 2015017123 A MX2015017123 A MX 2015017123A MX 2015017123 A MX2015017123 A MX 2015017123A MX 2015017123 A MX2015017123 A MX 2015017123A
Authority
MX
Mexico
Prior art keywords
nanoparticles
based compounds
lipid
platinum based
platinum compounds
Prior art date
Application number
MX2015017123A
Other languages
English (en)
Inventor
Sengupta Shiladitya
Roy Monideepa
SARKAR Arindam
Samad Hossain Sk
SENGUPTA Aniruddha
Kumar Dutta Pradip
Ansari Aasif
K Mandal Swadhin
Original Assignee
Invictus Oncology Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invictus Oncology Pvt Ltd filed Critical Invictus Oncology Pvt Ltd
Publication of MX2015017123A publication Critical patent/MX2015017123A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Abstract

La presente descripción se relaciona al campo de nanotecnología y agentes terapéuticos de cáncer. En particular, la presente descripción se relaciona a compuestos a base de platino que comprenden porción de platino, porción enlazadora y porción de lípido y nanopartículas correspondientes de los mismos. La descripción además se relaciona a la síntesis de los compuestos a base de platino, nanopartículas y composiciones que comprenden los compuestos/nanopartículas a base de platino. La descripción también se relaciona a métodos para manejar cáncer al emplear los compuestos de carbeno antedichos, los compuestos a base de platino, nanopartículas y composiciones de los mismos.
MX2015017123A 2013-06-14 2014-06-13 Compuestos de platino a base de lipido y nanoparticulas. MX2015017123A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1781DE2013 2013-06-14
PCT/US2014/042339 WO2014201376A2 (en) 2013-06-14 2014-06-13 Lipid-based platinum compounds and nanoparticles

Publications (1)

Publication Number Publication Date
MX2015017123A true MX2015017123A (es) 2016-08-03

Family

ID=52022859

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017123A MX2015017123A (es) 2013-06-14 2014-06-13 Compuestos de platino a base de lipido y nanoparticulas.
MX2020001262A MX2020001262A (es) 2013-06-14 2015-12-11 Compuestos de platino a base de lipido y nanoparticulas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001262A MX2020001262A (es) 2013-06-14 2015-12-11 Compuestos de platino a base de lipido y nanoparticulas.

Country Status (11)

Country Link
US (4) US10017531B2 (es)
EP (1) EP3007709B1 (es)
JP (2) JP6800748B2 (es)
CN (1) CN105705152B (es)
AU (2) AU2014278011B2 (es)
BR (1) BR112015031278B1 (es)
CA (1) CA2915357C (es)
MX (2) MX2015017123A (es)
RU (2) RU2679896C2 (es)
WO (2) WO2014201376A2 (es)
ZA (1) ZA201600099B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2679896C2 (ru) 2013-06-14 2019-02-14 Акамара Терапьютикс, Инк. Соединения на основе платины и липидов и наночастицы
KR102085190B1 (ko) * 2015-04-13 2020-03-05 더 유니버시티 오브 홍콩 Oled 어플리케이션용 금 착물
ES2918385T3 (es) * 2015-05-19 2022-07-15 Akamara Therapeutics Inc Proceso de preparacion de compuestos supramoleculares a base de platino
CN109678910B (zh) * 2016-01-25 2021-09-07 沈阳药科大学 一种化合物及其应用以及一种铂类配合物及其脂质体
KR20180105723A (ko) 2016-02-11 2018-09-28 인빅터스 온콜로지 피비티. 엘티디. 세포 신호전달 억제제, 이의 제형 및 이의 방법
CA3024387A1 (en) * 2016-05-18 2017-11-23 Akamara Therapeutics, Inc. Crystalline platinum-based compounds
CN106317124B (zh) * 2016-07-27 2018-08-21 东南大学 一种自旋交叉中空纳米球及其制备方法和应用
WO2018047090A1 (en) * 2016-09-07 2018-03-15 Akamara Therapeutics, Inc. Immune memory induction by platinum based compounds
CN108689939A (zh) * 2017-04-07 2018-10-23 厦门华绰生物医药科技有限公司 取代咪唑盐类化合物、其制备方法、药用组合物及其应用
CN107417752B (zh) * 2017-07-26 2020-05-05 中国科学院长春应用化学研究所 一类具有抗癌活性的化合物及其制备方法和应用
US20230092662A1 (en) * 2017-11-17 2023-03-23 Sarasija Suresh Cisplatin nanoparticle composition, method for the preparation thereof
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates
CN108579809B (zh) * 2018-01-23 2020-10-16 湖州师范学院 一种含氮杂环卡宾钯化合物的纳米颗粒催化剂及其制备方法
WO2020014387A1 (en) 2018-07-10 2020-01-16 Akamara Therapeutics, Inc. B-cell immunotherapy in cancer treatment
WO2020168283A1 (en) 2019-02-14 2020-08-20 Akamara Therapeutics, Inc. Compounds and methods for managing cancer through immune system
WO2020190907A1 (en) * 2019-03-18 2020-09-24 Kent State University Amphiphilic platinum (iv) prodrug and cancer treatment process
US20230398077A1 (en) * 2020-10-30 2023-12-14 The Regents Of The University Of California Silicasome nanocarrier for metal-based drug delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3783049A (en) * 1971-03-31 1974-01-01 Trw Inc Method of platinum diffusion
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4952676A (en) 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
WO1996037194A1 (en) 1995-05-26 1996-11-28 Somatix Therapy Corporation Delivery vehicles comprising stable lipid/nucleic acid complexes
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
DE19756236A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6218367B1 (en) 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
EP1734937A1 (en) 2004-03-26 2006-12-27 Cell Therapeutics Europe S.R.L. Nanoparticle formulations of platinum compounds
AU2005278924A1 (en) * 2004-09-01 2006-03-09 Platco Technologies (Proprietary) Limited Preparation of platinum(II) complexes
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
ATE449830T1 (de) * 2006-06-26 2009-12-15 Basf Se Verwendung von pt- und pd-bis- und tetracarbenkomplexen mit verbrückten carbenliganden in oleds
RU2538199C2 (ru) 2009-02-04 2015-01-10 Дзе Бригхэм Энд Вимен'З Хоспитэл, Инк. Наносоединения платины и способы их применения
CA2804228A1 (en) 2010-07-28 2012-02-02 Basf Se Phosphinic acid hydrazide flame retardant compositions
KR20140074880A (ko) * 2011-06-21 2014-06-18 메사추세츠 인스티튜트 오브 테크놀로지 암의 치료를 위한 조성물 및 방법
WO2013072295A1 (en) 2011-11-15 2013-05-23 Basf Se P-piperazine compounds as flame retardants
JP6228551B2 (ja) 2012-01-03 2017-11-08 インビクタス オンコロジー プライベート リミテッド リガンド−標的指向分子およびその方法
BR112014031421A2 (pt) * 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc composições para tratamento de câncer e métodos para produção das mesmas
JP6284476B2 (ja) 2012-06-28 2018-02-28 大八化学工業株式会社 難燃剤、該難燃剤を含有する難燃性水性樹脂組成物及び難燃性ウレタン樹脂組成物、並びにそれらの用途
RU2679896C2 (ru) 2013-06-14 2019-02-14 Акамара Терапьютикс, Инк. Соединения на основе платины и липидов и наночастицы

Also Published As

Publication number Publication date
RU2019101651A3 (es) 2019-07-17
BR112015031278A8 (pt) 2019-10-01
US10017531B2 (en) 2018-07-10
US20160145284A1 (en) 2016-05-26
MX2020001262A (es) 2020-09-22
RU2019101651A (ru) 2019-05-14
EP3007709B1 (en) 2021-12-08
RU2679896C2 (ru) 2019-02-14
AU2014278011A1 (en) 2016-01-07
CA2915357C (en) 2023-10-03
CN105705152B (zh) 2021-07-09
WO2014199352A2 (en) 2014-12-18
RU2737735C2 (ru) 2020-12-02
RU2016100741A (ru) 2017-07-24
US10081648B2 (en) 2018-09-25
BR112015031278B1 (pt) 2022-05-17
US20160122377A1 (en) 2016-05-05
WO2014201376A3 (en) 2015-02-05
US10730899B2 (en) 2020-08-04
WO2014201376A2 (en) 2014-12-18
US20200354394A1 (en) 2020-11-12
JP2016522220A (ja) 2016-07-28
AU2014278011B2 (en) 2020-03-19
EP3007709A2 (en) 2016-04-20
CA2915357A1 (en) 2014-12-18
EP3007709A4 (en) 2017-03-15
JP6800748B2 (ja) 2020-12-16
RU2016100741A3 (es) 2018-03-05
WO2014199352A3 (en) 2015-04-16
AU2020204076A1 (en) 2020-07-09
CN105705152A (zh) 2016-06-22
ZA201600099B (en) 2019-03-27
JP2020125296A (ja) 2020-08-20
US20190002489A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MX2020001262A (es) Compuestos de platino a base de lipido y nanoparticulas.
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
SG10201900948PA (en) Modified nucleotide linkers
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
EP3077399A4 (en) Methods useful in the synthesis of halichondrin b analogs
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
TWD164114S (zh) 行動電源之部分
ECSP14013327A (es) Compuestos con actividad nematicida
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
TWD159981S (zh) 化粧品容器
IN2015DN03898A (es)
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
BR112013023438A2 (pt) sistemas e métodos para melhorar o rendimento do etanol
HK1220033A1 (zh) 用於產生高頻帶激勵信號的混合因子的估計
IN2015DN03897A (es)
PH12016500924A1 (en) Anti-cancer agents and preparation thereof
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX2015007727A (es) 6-cloro-3-(fenil-d5)inden-1-ona y su uso.
IN2015DN00085A (es)
MX2015014470A (es) Analogos de combretastatina.
CR20150028A (es) Derivados de ariletinilo
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
CR20140531A (es) Derivados de ariletinilo

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: AKAMARA THERAPEUTICS, INC.

FG Grant or registration